Login to Your Account


Victory at last in DMD: Santhera phase III hits FDA-blessed lung function endpoint

By Randy Osborne
Staff Writer

Tuesday, May 13, 2014
Having scored landmark phase III success against Duchenne muscular dystrophy (DMD) with idebenone, an oral drug that does not depend on patients' mutational status, Santhera Pharmaceuticals AG is heading to the FDA to talk about next steps.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription